Physician profile
Wilfred Corredera
NPI 1891743365
$5,631.45
in general payments reported to CMS, 2019-2025
38 companies · $521 in 2025
The $521 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,009 · 2020: $1,361 · 2021: $1,035 · 2022: $759 · 2023: $493 · 2024: $453 · 2025: $521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,447 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,446.69 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,644.99 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $369.43 | 2019-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $336.62 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $297.29 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $262.11 | 2019-2022 | |
| Glaxosmithkline, LLC. | $254.22 | 2019-2022 | |
| Exact Sciences Corporation | $219.67 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $199.94 | 2019-2021 | |
| Amarin Pharma, INC. | $190.68 | 2019-2021 | |
| Corcept Therapeutics | $187.62 | 2024-2025 | Korlym |
| Regeneron Healthcare Solutions, INC. | $160.98 | 2019 | |
| Novartis Pharmaceuticals Corporation | $135.37 | 2019-2025 | |
| Xeris Pharmaceuticals, INC. | $131.35 | 2023-2025 | Keveyis, Gvoke Hypopen |
| Mannkind Corporation | $115.22 | 2020-2021 | |
| Esperion Therapeutics, INC. | $98.58 | 2020-2024 | Nexletol |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $95.08 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.58 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $87.39 | 2020-2022 | |
| Amgen INC. | $84.00 | 2021-2024 | Repatha, Otezla |
| Alexion Pharmaceuticals, INC. | $79.73 | 2021 | |
| Abbvie INC. | $64.61 | 2022-2024 | |
| Dexcom, INC. | $64.25 | 2021-2023 | Dexcom G6 Transmitter |
| Sunovion Pharmaceuticals INC. | $56.43 | 2020-2021 | |
| Mylan Specialty L.P. | $54.69 | 2019 | |
| Merck Sharp & Dohme LLC | $52.21 | 2019-2022 | |
| Lundbeck LLC | $44.13 | 2025 | Rexulti |
| Medtronic, INC. | $38.35 | 2021-2023 | Minimed 780g |
| Eisai INC. | $34.63 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $27.98 | 2022 | |
| Boston Scientific Corporation | $23.81 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $22.91 | 2020 | |
| Alnylam Pharmaceuticals INC. | $20.74 | 2020 | |
| Solventum Corporation | $20.50 | 2025 | Activ.A.C. |
| Horizon Therapeutics Plc | $18.77 | 2021 | |
| Allergan, INC. | $16.35 | 2020 | |
| Amryt Pharma Holdings LTD | $16.35 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $11.89 | 2020 | |
| Cequr Corporation | $4.00 | 2023 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wilfred Corredera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.